AMD: New treatments from intravitreal injections to gene therapy
March 3rd 2022Christina Y. Weng, MD, MBA, an associate professor of ophthalmology and surgical retina fellowship program director at Baylor College of Medicine in Houston, recently shared some standout therapies for macular degeneration.
Read More
AffaMed gets FDA IND clearance for AM712 to treat retinal vascular diseases
February 15th 2022AM712 is a novel bispecific biologic molecule specifically designed for ocular use. In pre-clinical studies, it demonstrated efficacy, ocular pharmacokinetics, and the desired safety profile supporting clinical exploration.
Read More
Unity provides Phase 1 study data for UBX1325
February 14th 2022During a presentation at the Bascom Palmer Eye Institute Angiogenesis, Exudation, and Degeneration 2022 conference, Robert Bhisitkul, MD, PhD, provided 24-week clinical data from the Phase 1 study, demonstrating that patients with DME and wAMD showed improved visual acuity through 24 weeks following a single dose of UBX1325.
Read More
Post hoc analysis of patients in avacincaptad pegol clinical trial shows growth of GA lesions slowed
February 11th 2022In a presentation at the Bascom Palmer Eye Institute’s 19th annual Angiogenesis, Exudation, and Degeneration 2022 Virtual Edition, Glenn J. Jaffe, MD, noted that the analysis showed, for the first time, a decreased growth rate in the central foveal area by a therapeutic intervention when compared with sham treatment.
Read More
Blocking Connexin-43 may improve diabetic retinopathy, AMD
February 11th 2022Dr. David S. Boyer describes how blocking Connexin-43 may improve the retinal vascular system function in patients with diabetes, potentially creating a future of oral medication for treatment of diabetic retinopathy and AMD.
Read More
CEBF virtual symposium showcases vision research from three Northeast Ohio institutions
February 2nd 2022Cleveland Eye Bank Foundation (CEBF) will feature nine researchers from three eye institutions on February 15, from 3 to 5 pm Eastern, for its second annual virtual vision research symposium.
Read More
Studies: Faricimab improved and maintained vision for patients with wet AMD, DME
January 24th 2022Across four studies, about half of eligible faricimab patients were able to go 4 months between treatments, and approximately three-quarters could be treated every 3 months or longer. Two papers published in The Lancet highlight one-year results.
Read More
Partnership develops video game software patented for age-related macular degeneration research
January 21st 2022A partnership that includes BALANCED Media|Technology, the Retina Foundation of the Southwest and Southern Methodist University is seeking a patent for machine learning software for OCT images aids in identity progression and treatment options
Read More
Second pivotal trial in RGX-314 clinical program to begin
January 12th 2022ASCENT, REGENXBIO’s Phase III clinical trial conducted in partnership with AbbVie, is expected to enroll patients in the United States and Canada, with pivotal trials expected to support BLA submission for RGX-314 in 2024.
Read More